1![Myelofibrosis / Janus kinase inhibitor / Splenomegaly / Myeloproliferative neoplasm / Ruxolitinib / Medical diagnosis / Polycythemia vera Myelofibrosis / Janus kinase inhibitor / Splenomegaly / Myeloproliferative neoplasm / Ruxolitinib / Medical diagnosis / Polycythemia vera](/pdf-icon.png) | Add to Reading ListSource URL: www.bcshguidelines.comLanguage: English - Date: 2015-09-20 08:20:56
|
---|
2![Needham & Company 15th Annual Healthcare Conference John Scarlett, M.D. President & CEO, Geron Corporation April 12, 2016 Needham & Company 15th Annual Healthcare Conference John Scarlett, M.D. President & CEO, Geron Corporation April 12, 2016](https://www.pdfsearch.io/img/f229d255a29fef337e94766a74cf36c1.jpg) | Add to Reading ListSource URL: www.geron.comLanguage: English - Date: 2016-04-17 19:35:18
|
---|
3![1 Dr Jürgen Thiele Institute for Pathology University of Cologne Kerpener Str. 62 1 Dr Jürgen Thiele Institute for Pathology University of Cologne Kerpener Str. 62](https://www.pdfsearch.io/img/5e000f1924516a92c3a01c63a72d7835.jpg) | Add to Reading ListSource URL: whobluebooks.iarc.frLanguage: English - Date: 2015-10-29 10:08:25
|
---|
4![Phase 2 trial of PRM-151, an anti-fibrotic agent, in patients with myelofibrosis: Stage 1 results Srdan Verstovsek1, Ruben Mesa2, Lynda Foltz3, Vikas Gupta4, John Mascarenhas5, Ellen Ritchie6, Ronald Hoffman5, Richard Phase 2 trial of PRM-151, an anti-fibrotic agent, in patients with myelofibrosis: Stage 1 results Srdan Verstovsek1, Ruben Mesa2, Lynda Foltz3, Vikas Gupta4, John Mascarenhas5, Ellen Ritchie6, Ronald Hoffman5, Richard](https://www.pdfsearch.io/img/6478b55422631656af8fae0f81bdcf6d.jpg) | Add to Reading ListSource URL: www.promedior.comLanguage: English - Date: 2015-02-08 17:25:15
|
---|
5![Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec Canada H9S 1A9 www.novartis.ca Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec Canada H9S 1A9 www.novartis.ca](https://www.pdfsearch.io/img/78414298a37a920cf1bd331896515f57.jpg) | Add to Reading ListSource URL: www.novartis.caLanguage: English - Date: 2015-05-13 10:22:06
|
---|
6![Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results S. Verstovsek1, R. Mesa2, L. Foltz3, V. Gupta4, J. Mascarenhas5, E. Ritchie6, R. Hoffman5, R. Silver6, W. J. Hong8, M. Kre Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results S. Verstovsek1, R. Mesa2, L. Foltz3, V. Gupta4, J. Mascarenhas5, E. Ritchie6, R. Hoffman5, R. Silver6, W. J. Hong8, M. Kre](https://www.pdfsearch.io/img/a4d21164024a2142e2bf1bab3912113e.jpg) | Add to Reading ListSource URL: www.promedior.comLanguage: English - Date: 2014-06-13 01:07:42
|
---|
7![670 Vol. 24, No. 9 September 2002 Comments? Questions? Email: Web: VetLearn.com • Fax: 670 Vol. 24, No. 9 September 2002 Comments? Questions? Email: Web: VetLearn.com • Fax:](https://www.pdfsearch.io/img/76313a861955e5314a873cdfa4f5da0e.jpg) | Add to Reading ListSource URL: www.2ndchance.infoLanguage: English - Date: 2014-02-04 14:24:27
|
---|
8![](https://www.pdfsearch.io/img/abfb10742ddfb9185753cd5055cfd03b.jpg) | Add to Reading ListSource URL: www.pbs.gov.auLanguage: English - Date: 2014-10-01 21:56:24
|
---|
9![New York State Cancer Registry Guide to Determine Reportability for Physician Medical Practices New York State Cancer Registry Guide to Determine Reportability for Physician Medical Practices](https://www.pdfsearch.io/img/4bd865935e58932eb314cfcb1ae81107.jpg) | Add to Reading ListSource URL: www.health.ny.govLanguage: English - Date: 2011-04-06 14:08:05
|
---|
10![Statement of Advice ruxolitinib (Jakavi®) 5mg, 15mg and 20mg Tablets Novartis Pharmaceuticals UK Ltd (No: 867/13) Statement of Advice ruxolitinib (Jakavi®) 5mg, 15mg and 20mg Tablets Novartis Pharmaceuticals UK Ltd (No: 867/13)](https://www.pdfsearch.io/img/c242ed625ffb755296d74a78e4ee2829.jpg) | Add to Reading ListSource URL: www.scottishmedicines.org.ukLanguage: English |
---|